NO20013115D0 - En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes - Google Patents

En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes

Info

Publication number: NO20013115D0
Authority: NO; Norway
Prior art keywords: diabetes; treatment; combination; insulin; insulin sensitizers
Prior art date: 1998-12-24

Application number

NO20013115A

Other languages

English (en)

Other versions

NO20013115L (no

Inventor

Mark D Erion

Paul Van Poelje

Original Assignee

Mets Asis Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-24

Filing date

2001-06-21

Publication date

2001-06-21

2001-06-21 Application filed by Mets Asis Therapeutics Inc filed Critical Mets Asis Therapeutics Inc

2001-06-21 Publication of NO20013115D0 publication Critical patent/NO20013115D0/no

2001-08-24 Publication of NO20013115L publication Critical patent/NO20013115L/no

Links

101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 title abstract 2
101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 title abstract 2
101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 title abstract 2
101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 title abstract 2
101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 title abstract 2
229940122355 Insulin sensitizer Drugs 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

NO20013115A 1998-12-24 2001-06-21 En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes NO20013115L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11471898P	1998-12-24	1998-12-24
PCT/US1999/030713 WO2000038666A2 (en)	1998-12-24	1999-12-22	A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number	Publication Date
NO20013115D0 true NO20013115D0 (no)	2001-06-21
NO20013115L NO20013115L (no)	2001-08-24

Family

ID=22357016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013115A NO20013115L (no)	1998-12-24	2001-06-21	En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes

Country Status (25)

Country	Link
EP (1)	EP1143955B1 (no)
JP (1)	JP2003515523A (no)
KR (3)	KR20070046210A (no)
CN (3)	CN1714866A (no)
AT (1)	ATE300288T1 (no)
AU (1)	AU771039B2 (no)
BR (1)	BR9917005A (no)
CA (1)	CA2354053A1 (no)
CZ (1)	CZ20012353A3 (no)
DE (1)	DE69926400T2 (no)
DK (1)	DK1143955T3 (no)
ES (1)	ES2246586T3 (no)
HK (1)	HK1046863B (no)
HU (1)	HUP0402506A3 (no)
ID (1)	ID30237A (no)
IL (2)	IL143569A0 (no)
MX (1)	MXPA01006511A (no)
NO (1)	NO20013115L (no)
NZ (1)	NZ512219A (no)
PL (1)	PL352756A1 (no)
PT (1)	PT1143955E (no)
RU (2)	RU2227749C2 (no)
SK (1)	SK9172001A3 (no)
WO (1)	WO2000038666A2 (no)
ZA (1)	ZA200105016B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6284748B1 (en)	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
US6312662B1 (en)	1998-03-06	2001-11-06	Metabasis Therapeutics, Inc.	Prodrugs phosphorus-containing compounds
KR100818845B1 (ko)	1998-09-09	2008-04-01	메타베이시스 테라퓨틱스, 인크.	신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
AU784370B2 (en) *	1999-12-22	2006-03-23	Metabasis Therapeutics, Inc.	Novel bisamidate phosphonate prodrugs
JP2003525944A (ja)	2000-03-08	2003-09-02	メタバシス・セラピューティクス・インコーポレイテッド	新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1372660A2 (en) *	2000-07-06	2004-01-02	Metabasis Therapeutics, Inc.	A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1340749A4 (en) *	2000-11-17	2007-09-05	Takeda Pharmaceutical	ISOXAZOLE DERIVATIVES
EP2223927B1 (en)	2002-05-13	2014-10-15	Metabasis Therapeutics, Inc.	Salts of a phosphonic acid based prodrug of PMEA
WO2003095665A2 (en)	2002-05-13	2003-11-20	Metabasis Therapeutics, Inc.	Pmea and pmpa cyclic producing synthesis
AU2003264256A1 (en) *	2002-09-04	2004-03-29	Dsm Ip Assets B.V.	A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
SI1611112T1 (sl) *	2003-02-11	2012-12-31	Vernalis (R&D) Limited	Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
JP4638355B2 (ja) *	2003-12-26	2011-02-23	協和発酵キリン株式会社	チアゾール誘導体
JP2008510018A (ja) *	2004-08-18	2008-04-03	メタバシス・セラピューティクス・インコーポレイテッド	フルクトース−１，６−ビスホスファターゼの新規チアゾール阻害物質
BRPI0519006A2 (pt) *	2004-12-13	2008-12-23	Daiichi Sankyo Co Ltd	uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
EP1825854A1 (en) *	2004-12-15	2007-08-29	Daiichi Sankyo Company, Limited	MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR
EP1889618A4 (en) *	2005-05-27	2010-11-24	Daiichi Sankyo Co Ltd	Combined drug for treating diabetes
EP1894930A4 (en)	2005-06-23	2010-06-23	Kyowa Hakko Kirin Co Ltd	THIAZOLE DERIVATIVE
US20100076037A1 (en)	2006-11-02	2010-03-25	Chiang Lillian W	Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CN103665043B (zh)	2012-08-30	2017-11-10	江苏豪森药业集团有限公司	一种替诺福韦前药及其在医药上的应用
US9631825B2 (en)	2012-12-18	2017-04-25	Nortek Air Solutions, Llc	Air filter assembly
AU2015217221A1 (en)	2014-02-13	2016-08-11	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
CN105481896A (zh) *	2015-12-03	2016-04-13	浙江大学	一种地马格列的制备方法
CN113416739B (zh) *	2021-06-24	2022-04-19	黑龙江八一农垦大学	鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4968790A (en) *	1988-08-12	1990-11-06	American Cyanamid Company	Antidiabetic phosphates
JPH03157377A (ja) *	1988-11-18	1991-07-05	Takeda Chem Ind Ltd	チオ尿素誘導体及びａｇｅ生成阻害剤
DE69014562T2 (de) *	1989-01-24	1995-06-22	Gensia Pharma	Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) *	1997-02-19	1999-01-12	Warner-Lambert Company	Sulfonylurea-glitazone combinations for diabetes
US6284748B1 (en) *	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
DE69819311T2 (de) *	1997-03-07	2004-07-29	Metabasis Therapeutics Inc., San Diego	Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6054587A (en) *	1997-03-07	2000-04-25	Metabasis Therapeutics, Inc.	Indole and azaindole inhibitors of fructose-1,6-bisphosphatase

1999
- 1999-12-22 PL PL99352756A patent/PL352756A1/xx not_active Application Discontinuation
- 1999-12-22 AU AU20583/00A patent/AU771039B2/en not_active Ceased
- 1999-12-22 BR BR9917005-1A patent/BR9917005A/pt not_active Application Discontinuation
- 1999-12-22 JP JP2000590620A patent/JP2003515523A/ja active Pending
- 1999-12-22 MX MXPA01006511A patent/MXPA01006511A/es active IP Right Grant
- 1999-12-22 ES ES99964313T patent/ES2246586T3/es not_active Expired - Lifetime
- 1999-12-22 CZ CZ20012353A patent/CZ20012353A3/cs unknown
- 1999-12-22 IL IL14356999A patent/IL143569A0/xx active IP Right Grant
- 1999-12-22 KR KR1020077008649A patent/KR20070046210A/ko not_active Ceased
- 1999-12-22 ID IDW00200101612A patent/ID30237A/id unknown
- 1999-12-22 CA CA002354053A patent/CA2354053A1/en not_active Abandoned
- 1999-12-22 CN CNA2005100806150A patent/CN1714866A/zh active Pending
- 1999-12-22 HK HK02108475.5A patent/HK1046863B/zh not_active IP Right Cessation
- 1999-12-22 CN CNB998163562A patent/CN100352505C/zh not_active Expired - Fee Related
- 1999-12-22 KR KR1020067022095A patent/KR20060114724A/ko not_active Ceased
- 1999-12-22 HU HU0402506A patent/HUP0402506A3/hu active IP Right Revival
- 1999-12-22 EP EP99964313A patent/EP1143955B1/en not_active Expired - Lifetime
- 1999-12-22 AT AT99964313T patent/ATE300288T1/de active
- 1999-12-22 DK DK99964313T patent/DK1143955T3/da active
- 1999-12-22 NZ NZ512219A patent/NZ512219A/xx not_active IP Right Cessation
- 1999-12-22 KR KR1020017008102A patent/KR100689943B1/ko not_active Expired - Fee Related
- 1999-12-22 DE DE69926400T patent/DE69926400T2/de not_active Expired - Lifetime
- 1999-12-22 RU RU2001120726/15A patent/RU2227749C2/ru not_active IP Right Cessation
- 1999-12-22 CN CNA2007101628889A patent/CN101164618A/zh active Pending
- 1999-12-22 WO PCT/US1999/030713 patent/WO2000038666A2/en not_active Ceased
- 1999-12-22 SK SK917-2001A patent/SK9172001A3/sk unknown
- 1999-12-22 PT PT99964313T patent/PT1143955E/pt unknown
2001
- 2001-06-05 IL IL143569A patent/IL143569A/en not_active IP Right Cessation
- 2001-06-19 ZA ZA200105016A patent/ZA200105016B/en unknown
- 2001-06-21 NO NO20013115A patent/NO20013115L/no not_active Application Discontinuation
2003
- 2003-10-31 RU RU2003132054/14A patent/RU2003132054A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL352756A1 (en)	2003-09-08
KR100689943B1 (ko)	2007-03-08
EP1143955B1 (en)	2005-07-27
ZA200105016B (en)	2002-09-19
HK1046863B (zh)	2008-07-25
AU2058300A (en)	2000-07-31
WO2000038666A3 (en)	2001-11-29
CN1350466A (zh)	2002-05-22
SK9172001A3 (en)	2002-04-04
KR20060114724A (ko)	2006-11-07
KR20010099942A (ko)	2001-11-09
DE69926400D1 (de)	2005-09-01
EP1143955A2 (en)	2001-10-17
BR9917005A (pt)	2002-04-02
CN100352505C (zh)	2007-12-05
PT1143955E (pt)	2005-11-30
MXPA01006511A (es)	2004-03-19
IL143569A (en)	2006-06-11
EP1143955A3 (en)	2002-08-28
HUP0402506A2 (hu)	2005-04-28
WO2000038666A2 (en)	2000-07-06
HK1046863A1 (zh)	2003-01-30
IL143569A0 (en)	2002-04-21
CN1714866A (zh)	2006-01-04
RU2227749C2 (ru)	2004-04-27
DK1143955T3 (da)	2005-11-14
KR20070046210A (ko)	2007-05-02
HUP0402506A3 (en)	2007-05-29
AU771039B2 (en)	2004-03-11
ES2246586T3 (es)	2006-02-16
JP2003515523A (ja)	2003-05-07
NO20013115L (no)	2001-08-24
ID30237A (id)	2001-11-15
DE69926400T2 (de)	2006-05-24
RU2003132054A (ru)	2005-04-20
NZ512219A (en)	2004-12-24
CA2354053A1 (en)	2000-07-06
CZ20012353A3 (cs)	2001-12-12
ATE300288T1 (de)	2005-08-15
CN101164618A (zh)	2008-04-23

Legal Events

Date	Code	Title	Description
2010-07-19	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20013115D0 (no)	2001-06-21	En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
IL157821A0 (en)	2004-03-28	Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
PT1112275E (pt)	2003-12-31	Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
BR0308928A (pt)	2005-01-04	Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
MY180762A (en)	2020-12-08	Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
NO20055832L (no)	2006-02-03	Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
SG146653A1 (en)	2008-10-30	Methods and reagents for the treatment of immunoinflammatory disorders
DK1426054T3 (da)	2011-12-12	Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
TW200604179A (en)	2006-02-01	Pyrazole derivatives, compositions containing such compounds and methods of use
NO20045056L (no)	2005-02-16	Fremgangsmater for behandling av hepatitt
PT1427409E (pt)	2008-11-27	Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
NO20045354L (no)	2004-12-22	Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
MY141528A (en)	2010-05-14	Anilinopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (pl)	2009-12-31	Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
AU7564396A (en)	1997-06-05	Rac-proteine kinase as therapeutic agent or in diagnostics
IL186356A0 (en)	2008-01-20	Method of treating of preventing type-2 diabetes
WO2003035048A3 (en)	2003-10-09	Methods for the treatment of osteoarthritis and compositions thereof
DE69924385D1 (de)	2005-04-28	Verwendung von angiotensin zur behandlung von krebsmetastasierung
UA35854A (uk)	2001-04-16	Спосіб лікування приховано протікаючого силікотуберкульозу